000275616 001__ 275616
000275616 005__ 20240229154944.0
000275616 0247_ $$2doi$$a10.21873/anticanres.16365
000275616 0247_ $$2pmid$$apmid:37097694
000275616 0247_ $$2ISSN$$a0250-7005
000275616 0247_ $$2ISSN$$a1791-7530
000275616 037__ $$aDKFZ-2023-00822
000275616 041__ $$aEnglish
000275616 082__ $$a610
000275616 1001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b0$$eFirst author$$udkfz
000275616 245__ $$aHelical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery: Long-term Results.
000275616 260__ $$aAttiki$$c2023
000275616 3367_ $$2DRIVER$$aarticle
000275616 3367_ $$2DataCite$$aOutput Types/Journal article
000275616 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1682512387_25681
000275616 3367_ $$2BibTeX$$aARTICLE
000275616 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275616 3367_ $$00$$2EndNote$$aJournal Article
000275616 500__ $$a#EA:E055#
000275616 520__ $$aAdjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery.In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively.The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up.Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.
000275616 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000275616 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275616 650_7 $$2Other$$aBreast cancer
000275616 650_7 $$2Other$$ahelical IMRT
000275616 650_7 $$2Other$$along-term results
000275616 650_7 $$2Other$$alymph node negative
000275616 650_7 $$2Other$$alymphedema
000275616 650_7 $$2Other$$aradiotherapy
000275616 650_7 $$2Other$$asecondary malignoma
000275616 650_7 $$2Other$$atomotherapy
000275616 7001_ $$aKlepper, Rudolf$$b1
000275616 7001_ $$0P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aHauswald, Henrik$$b2
000275616 7001_ $$aHoefel, Sebastian$$b3
000275616 7001_ $$aRaether, Luis$$b4
000275616 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b5$$udkfz
000275616 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b6
000275616 7001_ $$aSchempp, Michael$$b7
000275616 773__ $$0PERI:(DE-600)2145376-7$$a10.21873/anticanres.16365$$gVol. 43, no. 5, p. 2041 - 2053$$n5$$p2041 - 2053$$tAnticancer research$$v43$$x0250-7005$$y2023
000275616 909CO $$ooai:inrepo02.dkfz.de:275616$$pVDB
000275616 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275616 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275616 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000275616 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000275616 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000275616 9141_ $$y2023
000275616 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-15
000275616 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-15
000275616 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-15
000275616 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTICANCER RES : 2022$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000275616 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000275616 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000275616 9200_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000275616 980__ $$ajournal
000275616 980__ $$aVDB
000275616 980__ $$aI:(DE-He78)E055-20160331
000275616 980__ $$aUNRESTRICTED